200 related articles for article (PubMed ID: 36467125)
1. Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response.
Lombardo G; Nettis MA; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Bogdanova A; Sforzini L; Cleare AJ; Young AH; Dazzan P; Mondelli V; Pariante CM
Brain Behav Immun Health; 2022 Dec; 26():100561. PubMed ID: 36467125
[TBL] [Abstract][Full Text] [Related]
2. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Sforzini L; Bogdanova A; Cleare A; Young AH; Pariante CM; Mondelli V
Neuropsychopharmacology; 2021 Apr; 46(5):939-948. PubMed ID: 33504955
[TBL] [Abstract][Full Text] [Related]
3. Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Hellmann-Regen J; Clemens V; Grözinger M; Kornhuber J; Reif A; Prvulovic D; Goya-Maldonado R; Wiltfang J; Gruber O; Schüle C; Padberg F; Ising M; Uhr M; Friede T; Huber C; Manook A; Baghai TC; Rupprecht R; Heuser I
JAMA Netw Open; 2022 Sep; 5(9):e2230367. PubMed ID: 36103181
[TBL] [Abstract][Full Text] [Related]
4. Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2).
Husain MI; Cullen C; Umer M; Carvalho AF; Kloiber S; Meyer JH; Ortiz A; Knyahnytska Y; Husain MO; Giddens J; Diniz BS; Wang W; Young AH; Mulsant BH; Daskalakis ZJ
BMC Psychiatry; 2020 Apr; 20(1):173. PubMed ID: 32295565
[TBL] [Abstract][Full Text] [Related]
5. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
6. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH
Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.
Jha MK; Minhajuddin A; Chin-Fatt C; Greer TL; Carmody TJ; Trivedi MH
J Psychiatr Res; 2019 Jun; 113():165-171. PubMed ID: 30959227
[TBL] [Abstract][Full Text] [Related]
8. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
[TBL] [Abstract][Full Text] [Related]
9. The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression.
Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Sforzini L; Worrell C; Begum A; Brown M; Cleare AJ; Young AH; Pariante CM; Mondelli V
J Psychopharmacol; 2023 Jun; 37(6):531-538. PubMed ID: 37183855
[TBL] [Abstract][Full Text] [Related]
10. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
[TBL] [Abstract][Full Text] [Related]
11. Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.
Hasebe K; Mohebbi M; Gray L; Walker AJ; Bortolasci CC; Turner A; Berk M; Walder K; Maes M; Kanchanatawan B; Ashton MM; Berk L; Ng CH; Malhi GS; Singh AB; Dean OM
Acta Neuropsychiatr; 2022 Aug; 34(4):220-227. PubMed ID: 34937590
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
[TBL] [Abstract][Full Text] [Related]
13. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
Trials; 2015 Sep; 16():410. PubMed ID: 26374703
[TBL] [Abstract][Full Text] [Related]
14. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment.
Krynicki CR; Dazzan P; Pariante CM; Barnes NM; Vincent RC; Roberts A; Giordano A; Watson A; Suckling J; Barnes TRE; Husain N; Jones PB; Joyce E; Lawrie SM; Lewis S; Deakin B; Upthegrove R;
Brain Behav Immun; 2021 Jan; 91():498-504. PubMed ID: 33161162
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
17. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.
Soczynska JK; Kennedy SH; Alsuwaidan M; Mansur RB; Li M; McAndrews MP; Brietzke E; Woldeyohannes HO; Taylor VH; McIntyre RS
Bipolar Disord; 2017 May; 19(3):198-213. PubMed ID: 28599348
[TBL] [Abstract][Full Text] [Related]
18. Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.
Husain MI; Chaudhry IB; Khoso AB; Kiran T; Khan N; Ahmad F; Hodsoll J; Husain MO; Naqvi HA; Nizami AT; Chaudhry N; Khan HA; Minhas F; Meyer JH; Ansari MA; Mulsant BH; Husain N; Young AH
JAMA Netw Open; 2023 Feb; 6(2):e230147. PubMed ID: 36808239
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
Shelton RC; Pencina MJ; Barrentine LW; Ruiz JA; Fava M; Zajecka JM; Papakostas GI
J Clin Psychiatry; 2015 Dec; 76(12):1635-41. PubMed ID: 26613389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
